DaVita vs Kymera Therapeutics

DaVita (DVA), health care, and Kymera Therapeutics (KYMR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

DaVita is worth $10.9B on the stock market and Kymera Therapeutics $10.4B: DaVita is valued at 5% more. DaVita's operating margin in its latest fiscal year was 15.0% and Kymera Therapeutics's -891%. Over the past year DaVita's share price has moved +49.5% and Kymera Therapeutics's +95.7%.

Key facts

DaVita market value
$10.9B
Kymera Therapeutics market value
$10.4B
DaVita P/E
13.1
DaVita revenue
$13.6BFY to 2025-12-31
Kymera Therapeutics revenue
$39.2MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

DaVita vs Kymera Therapeutics: every measure side by side
Measure DaVita Kymera Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.9Bhigher$10.4Blower
Revenue$13.6Bhigher$39.2Mlower
Earnings$746.8Mhigher-$311.4Mlower
Employees78,000higher285lower
Total assets$17.5Bhigher$1.7Blower
Valuation
P/E13.1—
P/S0.8lower265higher
P/B—6.4
Dividend yield0.00%0.00%
Profitability
Operating margin15.0%higher-891%lower
Balance sheet
Net assets-$651.1Mlower$1.6Bhigher
Total liabilities$16.3Bhigher$163.1Mlower
Total debt$10.3B—
Cash on hand$676.4Mhigher$357Mlower
Price change
Today-0.70%higher-3.44%lower
1 year+49.5%lower+95.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

DaVita only (2)

Kymera Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns DVA · Who owns KYMR

Further comparisons

Learn

Questions and answers

Which is bigger, DaVita or Kymera Therapeutics?

By market value, DaVita is the larger: $10.9B against $10.4B for Kymera Therapeutics. By revenue in its latest fiscal year, DaVita is the larger: $13.6B against $39.2M for Kymera Therapeutics.

Which has the higher operating margin?

DaVita: 15.0%, against -891% for Kymera Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both DaVita and Kymera Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold DaVita and 1 holds Kymera Therapeutics.

Cite this page

Funkfolio, “DaVita vs Kymera Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/dva-vs-kymr

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.